Cognitive functioning of postmenopausal breast cancer patients before adjuvant systemic therapy, and its association with medical and psychological factors

Critical Reviews in Oncology/Hematology

Volumn 76, Issue 2, 2010, Pages 133-141

  Schilder, C M T ^a   Seynaeve, C ^b   Linn, S C ^a   Boogerd, W ^a,c   Beex, L V A M ^d   Gundy, C M ^a   Nortier, J W R ^e   van de Velde, C J H ^e   van Dam, F S A M ^a   Schagen, S B ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c Slotervaart Medical Center   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adjuvant systemic treatment; Breast cancer; Cognitive function; Neuropsychological testing; Postmenopausal; Psychological function

Indexed keywords

EXEMESTANE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGE DISTRIBUTION; AGED; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; COGNITION; COGNITIVE DEFECT; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; INTELLIGENCE QUOTIENT; MAJOR CLINICAL STUDY; MENTAL PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PATIENT ATTITUDE; POSTMENOPAUSE; PROGNOSIS; REPRODUCTION; REVIEW; SOCIAL PSYCHOLOGY; SYSTEMIC THERAPY; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANDROSTADIENES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COGNITION DISORDERS; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; INTELLIGENCE TESTS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEUROPSYCHOLOGICAL TESTS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TAMOXIFEN;

EID: 77957904566     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.11.001     Document Type: Review

References (43)

1. Schagen S.B., Vardy J. Cognitive dysfunction in people with cancer. Lancet Oncol 2007, 8:852-853.
2. Bender C.M., Sereika S.M., Berga S.L., et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006, 15:422-430.
3. Hermelink K., Untch M., Lux M.P., et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007, 109:1905-1913.
4. Hurria A., Rosen C., Hudis C., et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc 2006, 54:925-931.
5. Ahles T.A., Saykin A.J., McDonald B.C., et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Res Treat 2008, 110:143-152.
6. Fan H.G., Houede-Tchen N., Yi Q.L., et al. Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 2005, 23:8025-8032.
7. Quesnel C., Savard J., Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat 2009, 116(1):113-123.
8. Wefel J.S., Lenzi R., Theriault R., Buzdar A.U., Cruickshank S., Meyers C.A. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004, 101:466-475.
9. Jenkins V., Shilling V., Deutsch G., et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006, 94:828-834.
10. Schagen S.B., Muller M.J., Boogerd W., Mellenbergh G.J., Van Dam F.S. Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 2006, 98:1742-1745.
11. Stewart A., Collins B., Mackenzie J., Tomiak E., Verma S., Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 2008, 17:122-130.
12. Shilling V., Jenkins V., Trapala I.S. The (mis)classification of chemo-fog-methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 2006, 95:125-129.
13. Ahles T.A., Saykin A.J. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer 2007, 7:192-201.
14. Newman S., Stygall J., Hirani S., Shaefi S., Maze M. Postoperative cognitive dysfunction after noncardiac surgery: a systematic review. Anesthesiology 2007, 106:572-590.
15. Weuve J., Kang J.H., Manson J.E., Breteler M.M., Ware J.H., Grodstein F. Physical activity, including walking, and cognitive function in older women. JAMA 2004, 292:1454-1461.
16. Wilson R.S., Mendes De Leon C.F., Barnes L.L., et al. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 2002, 287:742-748.
17. Gregg E.W., Yaffe K., Cauley J.A., et al. Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 2000, 160:174-180.
18. Skoog I., Lernfelt B., Landahl S., et al. 15-year longitudinal study of blood pressure and dementia. Lancet 1996, 347:1141-1145.
19. McLay R.N., Maki P.M., Lyketsos C.G. Nulliparity and late menopause are associated with decreased cognitive decline. J Neuropsychiatry Clin Neurosci 2003, 15:161-167.
20. Schilder C.M., Eggens P.C., Seynaeve C., et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009, 48:76-85.
21. Van der Meulen E.F., Schmand B., van Campen J.P., et al. The seven minute screen: a neurocognitive screening test highly sensitive to various types of dementia. J Neurol Neurosurg Psychiatry 2004, 75:700-705.
22. Schmand B., Lindeboom J., van Harskamp F. De Nederlandse Leestest voor Volwassenen 1992, Swets & Zeitlinger, Lisse.
23. Chavez-MacGregor M., Elias S.G., Onland-Moret N.C., et al. Postmenopausal breast cancer risk and cumulative number of menstrual cycles. Cancer Epidemiol Biomarkers Prev 2005, 14:799-804.
24. Deeg D.J.H., Knipscheer C.P.M., van Tilburg W. Autonomy and well-being in the aging population: concepts and design of the Longitudinal Aging Study Amsterdam. NIG-trend-studies 1993, Netherlands Institute of Gerontology, Bunnik.
25. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
26. Frojdh K., Hakansson A., Karlsson I. The Hopkins Symptom Checklist-25 is a sensitive case-finder of clinically important depressive states in elderly people in primary care. Int J Geriatr Psychiatry 2004, 19:386-390.
27. Hadjiev D.I., Mineva P.P. Antihypertensive treatment in elderly hypertensives without a history of stroke and the risk of cognitive disorders. Acta Neurol Scand 2008, 118:139-145.
28. McGuinness B., Todd S., Passmore P., Bullock R. The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst Rev 2006, CD004034.
29. Cukierman-Yaffe T., Gerstein H.C., Williamson J.D., et al. Relationship between baseline glycemic control and cognitive function in individuals with type 2 diabetes and other cardiovascular risk factors: the action to control cardiovascular risk in diabetes-memory in diabetes (ACCORD-MIND) trial. Diabetes Care 2009, 32:221-226.
30. Birge S.J., McEwen B.S., Wise P.M. Effects of estrogen deficiency on brain function. Implications for the treatment of postmenopausal women. Postgrad Med 2001, [Spec No: 11-6].
31. Smith C.A., McCleary C.A., Murdock G.A., et al. Lifelong estrogen exposure and cognitive performance in elderly women. Brain Cogn 1999, 39:203-218.
32. Low L.F., Anstey K.J., Jorm A.F., Rodgers B., Christensen H. Reproductive period and cognitive function in a representative sample of naturally postmenopausal women aged 60-64 years. Climacteric 2005, 8:380-389.
33. Geerlings M.I., Ruitenberg A., Witteman J.C., et al. Reproductive period and risk of dementia in postmenopausal women. JAMA 2001, 285:1475-1481.
34. Biessels G.J., Deary I.J., Ryan C.M. Cognition and diabetes: a lifespan perspective. Lancet Neurol 2008, 7:184-190.
35. van den Burg W., Saan R.J., Deelman B.G. 15-woordentest. Provisional manual 1985, University Hospital, Department of Neuropsychology, Groningen.
36. Lindeboom J., Schmand B., Tulner L., Walstra G., Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry 2002, 73:126-133.
37. Wechsler D. Wechsler Memory Scale: Revised 1987, Psychological Corporation, New York.
38. Hammes J. De Stroop kleur-woord test. Handleiding 1978, Swets & Zeitlinger, Lisse. second ed.
39. Reitan R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 1958, 8:271-276.
40. Alpherts W., Aldenkamp A.P. FePsy: the iron psyche 1994, Instituut voor Epilepsiebestrijding, Heemstede.
41. Van der Elst W., van Boxtel M.P., Van Breukelen G.J., Jolles J. Normative data for the Animal, Profession and Letter M Naming verbal fluency tests for Dutch speaking participants and the effects of age, education, and sex. J Int Neuropsychol Soc 2006, 12:80-89.
42. Schmand B, Groenink S.C., van den Dungen M. [Letter fluency: psychometric properties and Dutch normative data] Letterfluency: psychometrische eigenschappen en Nederlandse normen. Tijdschr Gerontol Geriatr 2008, 39:64-76.
43. Wechsler D. WAIS-III Nederlandstalige Bewerking. Technische Handleiding 2000, Swets & Zeitlinger, Lisse.